Rationale and design of a randomised controlled trial testing the effect of personalised diet in individuals with pre-diabetes or type 2 diabetes mellitus treated with metformin

Thaw D Htet, Anastasia Godneva, Zhixin Liu, Eliza Chalmers, Dmitry Kolobkov, Jennifer R Snaith, Renee Richens, Krisztina Toth, Mark Danta, Tien-Ming Hng, Eran Elinav, Eran Segal, Jerry R Greenfield, Dorit Samocha-Bonet, Thaw D Htet, Anastasia Godneva, Zhixin Liu, Eliza Chalmers, Dmitry Kolobkov, Jennifer R Snaith, Renee Richens, Krisztina Toth, Mark Danta, Tien-Ming Hng, Eran Elinav, Eran Segal, Jerry R Greenfield, Dorit Samocha-Bonet

Abstract

Introduction: Metformin and diets aimed at promoting healthy body weight are the first line in treating type 2 diabetes mellitus (T2DM). Clinical practice, backed by clinical trials, suggests that many individuals do not reach glycaemic targets using this approach alone. The primary aim of the Personalised Medicine in Pre-diabetes-Towards Preventing Diabetes in Individuals at Risk (PREDICT) Study is to test the efficacy of personalised diet as adjuvant to metformin in improving glycaemic control in individuals with dysglycaemia.

Methods and analysis: PREDICT is a two-arm, parallel group, single-masked randomised controlled trial in adults with pre-diabetes or early-stage T2DM (with glycated haemoglobin (HbA1c) up to 8.0% (64 mmol/mol)), not treated with glucose-lowering medication. PREDICT is conducted at the Clinical Research Facility at the Garvan Institute of Medical Research (Sydney). Enrolment of participants commenced in December 2018 and expected to complete in December 2021. Participants are commenced on metformin (Extended Release, titrated to a target dose of 1500 mg/day) and randomised with equal allocation to either (1) the Personalised Nutrition Project algorithm-based diet or (2) low-fat high-dietary fibre diet, designed to provide caloric restriction (75%) in individuals with body mass index >25 kg/m2. Treatment duration is 6 months and participants visit the Clinical Research Facility five times over approximately 7 months. The primary outcome measure is HbA1c. The secondary outcomes are (1) time of interstitial glucose <7.8 mmol/L and (2) glycaemic variability (continuous glucose monitoring), (3) body weight, (4) fat mass and (5) abdominal visceral fat volume (dual-energy X-ray absorptiometry), serum (6) low-density lipoprotein cholesterol (7) high-density lipoprotein cholesterol and (8) triglycerides concentrations, (9) blood pressure, and (10) liver fat (Fibroscan).

Ethics and dissemination: The study has been approved by the St Vincent's Hospital Human Research Ethics Committee (File 17/080, Sydney, Australia) and the Weizmann Institutional Review Board (File 528-3, Rehovot, Israel). The findings will be published in peer-reviewed open access medical journals.

Trial registration number: NCT03558867; Pre-results.

Keywords: diabetes & endocrinology; nutrition & dietetics.

Conflict of interest statement

Competing interests: EE and ES are paid consultants of the company DayTwo. MD has received travel support and speaker fees from Gilead, Abbvie and Merck. All other authors declare they have no conflict of interest.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Screenshots of the smartphone application used daily by participants in the Personalised Medicine in Pre-diabetes—Towards Preventing Diabetes in Individuals at Risk Study. Participants randomised to the personalised diet arm receive scores for each meal. Panels (A) and (B) depict two meal options selected by an individual in the study where two isocaloric breakfasts are predicted to result in modest (A) or exaggerated (B) postprandial glycaemic responses. The daily energy intake and macronutrient breakdown are provided to each of the study participants (C).

References

    1. Stefan N, Fritsche A, Schick F, et al. . Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol 2016;4:789–98. 10.1016/S2213-8587(16)00082-6
    1. NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016;387:1513–30. 10.1016/S0140-6736(16)00618-8
    1. Hostalek U. Global epidemiology of prediabetes - present and future perspectives. Clin Diabetes Endocrinol 2019;5:5.
    1. IDF Diabetes Atlas 8th edition, 2017. International Diabetes Federation. Available:
    1. Evert AB, Dennison M, Gardner CD, et al. . Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care 2019;42:731–54. 10.2337/dci19-0014
    1. Ahlqvist E, Storm P, Käräjämäki A, et al. . Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018;6:361–9. 10.1016/S2213-8587(18)30051-2
    1. Bailey CJ. Metformin: historical overview. Diabetologia 2017;60:1566–76. 10.1007/s00125-017-4318-z
    1. Davies MJ, D'Alessio DA, Fradkin J, et al. . Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 2018;41:2669–701. 10.2337/dci18-0033
    1. Florez JC. The pharmacogenetics of metformin. Diabetologia 2017;60:1648–55. 10.1007/s00125-017-4335-y
    1. Samocha-Bonet D, Debs S, Greenfield JR. Prevention and treatment of type 2 diabetes: a Pathophysiological-Based approach. Trends Endocrinol Metab 2018;29:370–9. 10.1016/j.tem.2018.03.014
    1. Kahn SE, Haffner SM, Heise MA, et al. . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–43. 10.1056/NEJMoa066224
    1. TODAY Study Group, Zeitler P, Hirst K, et al. . A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012;366:2247–56. 10.1056/NEJMoa1109333
    1. Lachin JM, Christophi CA, Edelstein SL, et al. . Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes 2007;56:1153–9. 10.2337/db06-0918
    1. Aroda VR, Knowler WC, Crandall JP, et al. . Metformin for diabetes prevention: insights gained from the diabetes prevention Program/Diabetes prevention program outcomes study. Diabetologia 2017;60:1601–11. 10.1007/s00125-017-4361-9
    1. American Diabetes Association 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42:S13–28. 10.2337/dc19-S002
    1. Zeevi D, Korem T, Zmora N, et al. . Personalized nutrition by prediction of glycemic responses. Cell 2015;163:1079–94. 10.1016/j.cell.2015.11.001
    1. Australian Government National Health and Medical Research Council Australian guide to healthy eating, 2015. Available:
    1. Garvey WT, Mechanick JI, Brett EM, et al. . American association of clinical endocrinologists and American College of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 2016;22 Suppl 3:1–203. 10.4158/
    1. Lamb EJ, Tomson CRV, Roderick PJ, et al. . Estimating kidney function in adults using formulae. Ann Clin Biochem 2005;42:321–45. 10.1258/0004563054889936
    1. Meyerowitz-Katz G, Seelan S, Gaur P, et al. . Detecting the hidden burden of pre-diabetes and diabetes in Western Sydney. Diabetes Res Clin Pract 2019;151:247–51. 10.1016/j.diabres.2019.04.019
    1. Saghaei M, Saghaei S. Implementation of an open-source customizable minimization program for allocation of patients to parallel groups in clinical trials. J Biomed Sci Eng 2011;04:734–9. 10.4236/jbise.2011.411090
    1. Kozan P, Blythe JC, Greenfield JR, et al. . The effect of buffering high acid load meal with sodium bicarbonate on postprandial glucose metabolism in Humans-A randomized placebo-controlled study. Nutrients 2017;9:861. 10.3390/nu9080861
    1. Chen DL, Liess C, Poljak A, et al. . Phenotypic characterization of insulin-resistant and insulin-sensitive obesity. J Clin Endocrinol Metab 2015;100:4082–91. 10.1210/jc.2015-2712
    1. Tang A, Coster ACF, Tonks KT, et al. . Longitudinal changes in insulin resistance in normal weight, overweight and obese individuals. J Clin Med 2019;8. 10.3390/jcm8050623
    1. Eddowes PJ, Sasso M, Allison M, et al. . Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156:1717–30. 10.1053/j.gastro.2019.01.042
    1. Mendes-Soares H, Raveh-Sadka T, Azulay S, et al. . Assessment of a personalized approach to predicting postprandial glycemic responses to food among individuals without diabetes. JAMA Netw Open 2019;2:e188102. 10.1001/jamanetworkopen.2018.8102
    1. Australian food, supplement and nutrient database (AUSNUT) 2011-2013: food standards Australia New Zealand; 2016.
    1. Grech A, Rangan A, Allman-Farinelli M. Macronutrient Composition of the Australian Population’s Diet; Trends from Three National Nutrition Surveys 1983, 1995 and 2012. Nutrients 2018;10:1045 10.3390/nu10081045
    1. Mifflin MD, St Jeor ST, Hill LA, et al. . A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr 1990;51:241–7. 10.1093/ajcn/51.2.241
    1. James BL, Loken E, Roe LS, et al. . Validation of the diet satisfaction questionnaire: a new measure of satisfaction with diets for weight management. Obes Sci Pract 2018;4:506–14. 10.1002/osp4.299
    1. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther 2009;11 Suppl 1:S-55–S-67. 10.1089/dia.2008.0132
    1. Marjot T, Moolla A, Cobbold JF, et al. . Non-Alcoholic fatty liver disease in adults: current concepts in etiology, outcomes and management. Endocrine Reviews 2020;41:66–117. 10.1210/endrev/bnz009
    1. Green CJ, Marjot T, Tomlinson JW, et al. . Of mice and men: is there a future for metformin in the treatment of hepatic steatosis? Diabetes Obes Metab 2019;21:749–60. 10.1111/dom.13592
    1. Musso G, Cassader M, Rosina F, et al. . Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885–904. 10.1007/s00125-011-2446-4
    1. Sawangjit R, Chongmelaxme B, Phisalprapa P, et al. . Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a PRISMA-compliant systematic review and network meta-analysis. Medicine 2016;95:e4529. 10.1097/MD.0000000000004529
    1. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999;20:489–503. 10.2165/00002018-199920060-00003
    1. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia 2016;59:426–35. 10.1007/s00125-015-3844-9
    1. de Jager J, Kooy A, Lehert P, et al. . Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010;340:c2181. 10.1136/bmj.c2181
    1. Reinstatler L, YP Q, Williamson RS, et al. . Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements. Diabetes Care 2012;35:327–33.
    1. DeFronzo R, Fleming GA, Chen K, et al. . Metformin-Associated lactic acidosis: current perspectives on causes and risk. Metabolism 2016;65:20–9. 10.1016/j.metabol.2015.10.014
    1. Jönsson T, Granfeldt Y, Ahrén B, et al. . Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study. Cardiovasc Diabetol 2009;8:35. 10.1186/1475-2840-8-35
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403. 10.1056/NEJMoa012512
    1. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. . 10-Year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet 2009;374:1677–86. 10.1016/S0140-6736(09)61457-4
    1. Pasolli E, Asnicar F, Manara S, et al. . Extensive unexplored human microbiome diversity revealed by over 150,000 genomes from metagenomes spanning age, geography, and lifestyle. Cell 2019;176:649–62. 10.1016/j.cell.2019.01.001
    1. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012;9:357–9. 10.1038/nmeth.1923
    1. Korem T, Zeevi D, Suez J, et al. . Growth dynamics of gut microbiota in health and disease inferred from single metagenomic samples. Science 2015;349:1101–6. 10.1126/science.aac4812
    1. Harris PA, Taylor R, Minor BL, et al. . The REDCap Consortium: building an international community of software platform partners. J Biomed Inform 2019;95:103208. 10.1016/j.jbi.2019.103208
    1. Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81. 10.1016/j.jbi.2008.08.010

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel